(Reuters) - A combination of Vertex Pharmaceuticals Inc's VRTX.O cystic fibrosis drugs succeeded in improving lung function in a pair of closely watched late-stage trials, likely offering a potential new treatment for thousands more patients with the rare lung disease and sending Vertex shares soaring.










Source: Vertex cystic fibrosis combo succeeds in key late-stage trials

David Cottle

UBB Owner & Administrator